Literature DB >> 7647039

Transforming potential of the insulin receptor substrate 1.

C D'Ambrosio1, S R Keller, A Morrione, G E Lienhard, R Baserga, E Surmacz.   

Abstract

The role of the insulin receptor substrate 1 (IRS-1) in cellular transformation was studied in R- cells, which are 3T3-like fibroblasts derived from mouse embryos with a targeted disruption of the insulin-like growth factor I receptor gene. These cells cannot be transformed by oncogenes that readily transform cells originating from wild-type littermate embryos (or other 3T3-like cells). In the present study, we demonstrate that in R- cells, the overexpression of the functional IRS-1 protein was sufficient to induce a mitogenic response to insulin but did not promote transformation, as measured by colony formation in soft agar. The coexpression of IRS-1 and the SV40 T antigen, however, induced transformation. Conversely, expression of an antisense IRS-1 RNA reversed the transformed phenotype in wild-type cells carrying the T antigen. Since the type 1 insulin-like growth factor receptor, by itself, is fully transforming, we propose the hypothesis that the transforming competence of this receptor is based on at least two signaling pathways, one of which is IRS-1-dependent, whereas the other(s) can be substituted with the SV40 T antigen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647039

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  24 in total

1.  A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype.

Authors:  S Tanaka; J R Wands
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

2.  Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis.

Authors:  D Nehrbass; F Klimek; P Bannasch
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

3.  Therapeutic destruction of insulin receptor substrates for cancer treatment.

Authors:  Hadas Reuveni; Efrat Flashner-Abramson; Lilach Steiner; Kirill Makedonski; Renduo Song; Alexei Shir; Meenhard Herlyn; Menashe Bar-Eli; Alexander Levitzki
Journal:  Cancer Res       Date:  2013-05-07       Impact factor: 12.701

Review 4.  Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling.

Authors:  David N Boone; Adrian V Lee
Journal:  Crit Rev Oncog       Date:  2012

5.  Insulin-like growth factor II stimulates cell proliferation through the insulin receptor.

Authors:  A Morrione; B Valentinis; S Q Xu; G Yumet; A Louvi; A Efstratiadis; R Baserga
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

6.  Insulin-like growth factor I receptor signaling in transformation by src oncogenes.

Authors:  B Valentinis; A Morrione; S J Taylor; R Baserga
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

7.  Association of insulin receptor substrate 1 with simian virus 40 large T antigen.

Authors:  Z L Fei; C D'Ambrosio; S Li; E Surmacz; R Baserga
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

8.  IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype.

Authors:  Guido T Bommer; Ying Feng; Ayaka Iura; Thomas J Giordano; Rork Kuick; Hüseyin Kadikoy; Deanna Sikorski; Rong Wu; Kathleen R Cho; Eric R Fearon
Journal:  J Biol Chem       Date:  2009-10-20       Impact factor: 5.157

9.  IGF-IR-dependent expression of Survivin is required for T-antigen-mediated protection from apoptosis and proliferation of neural progenitors.

Authors:  E Gualco; K Urbanska; G Perez-Liz; T Sweet; F Peruzzi; K Reiss; L Del Valle
Journal:  Cell Death Differ       Date:  2009-10-16       Impact factor: 15.828

10.  Expression and function of the insulin receptor substrate proteins in cancer.

Authors:  Katerina Mardilovich; Shannon L Pankratz; Leslie M Shaw
Journal:  Cell Commun Signal       Date:  2009-06-17       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.